US · TVGNW
Tevogen Bio Holdings Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Warren, NJ 07059
- Website
- tevogen.com
Price · as of 2024-12-31
$0.03
Market cap 9.29M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 |
AI valuation
Our deep-learning model estimates Tevogen Bio Holdings Inc.'s (TVGNW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.03
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TVGNW | Tevogen Bio Holdings Inc. | $0.03 | 9.29M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 27.16% | 2087.12% | -306.17% | -0.43 | -291.05 | 0.26 | 0.16 | -0.12 | 2330000.00% | — | 4449.00% | — | -1.33 | 467.53% | — | 0.00% | — | — | — | — | — |
| APM | Aptorum Group Limited | $0.78 | 4.95M | +30,801% | — | — | — | -1.20 | 0.24 | — | -2.03 | -4.65 | 0.24 | 0.00% | — | — | -18.56% | -15.20% | -23.21% | 0.16 | -25.84 | 0.22 | 0.20 | -0.66 | 2581.00% | -10000.00% | -8459.00% | -23.24% | -0.27 | -4.77% | 0.00% | 0.00% | 0.00% | -2.00 | -6.39 | — | -6.61 |
| CING | Cingulate Inc. | $6.27 | 35.15M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| COCP | Cocrystal Pharma, Inc. | $1.05 | 10.76M | — | — | — | — | -0.99 | 1.82 | — | -0.52 | 0.00 | 1.82 | 0.00% | — | — | -97.50% | -1066.39% | -78.29% | 0.19 | — | 4.77 | 4.56 | 0.45 | 9042632.00% | — | 1156.00% | -95.36% | -6.79 | -983.78% | 0.00% | 0.00% | 0.00% | -0.52 | -0.56 | — | -35.62 |
| DWTX | Dogwood Therapeutics, Inc… | $2.85 | 5.45M | — | — | — | — | -0.55 | 0.11 | — | -0.61 | -0.71 | -0.51 | 0.00% | — | — | -36.28% | -37.33% | -25.08% | 0.24 | -132.63 | 5.21 | 4.67 | -0.06 | 7759.00% | — | 8049.00% | -129.59% | -2.77 | -26.84% | 0.00% | 0.00% | 0.01% | -0.62 | -0.86 | — | -1.22 |
| EVGN | Evogene Ltd. | $0.88 | 7.65M | +2,548% | -33% | — | — | -0.47 | -5.81 | 0.99 | -0.39 | — | -0.62 | 39.81% | -255.36% | -193.69% | -340.58% | 381.57% | -39.69% | -8.87 | -175.27 | 1.15 | 0.90 | 0.16 | -4474.00% | 5090.00% | -910.00% | -241.06% | -1.05 | 356.85% | 0.00% | 0.00% | 0.00% | -0.28 | -0.29 | 0.70 | -10.92 |
| IMRN | Immuron Limited | $0.77 | 4.96M | +2,352% | +18,330% | — | — | -3.14 | 2.04 | 2.25 | -2.00 | — | 2.04 | 65.39% | -73.34% | -71.58% | -50.30% | -304.73% | -40.68% | 0.01 | -731.63 | 5.07 | 3.39 | 0.51 | -2623.00% | 4863.00% | 436.00% | -37.47% | -3.12 | -349.90% | 0.00% | 0.00% | 0.00% | -1.99 | -1.73 | 1.46 | -6.75 |
| INAB | IN8bio, Inc. | $1.70 | 7.88M | — | — | — | — | -13.04 | 27.41 | — | -14.50 | — | 27.41 | 0.00% | — | — | -154.44% | -359.44% | -111.38% | 0.35 | — | 4.08 | 3.61 | 0.23 | -4300.00% | — | 131.00% | -6.11% | -7.83 | -286.41% | 0.00% | 0.00% | 0.00% | -12.84 | -16.11 | — | 24.43 |
| MBIO | Mustang Bio, Inc. | $1.01 | 7.37M | — | — | — | — | -0.58 | -2.34 | — | -0.21 | — | -2.34 | 0.00% | — | — | 840.11% | 241.62% | -116.47% | -0.23 | 3249.00 | 0.68 | 0.57 | 0.40 | -5717.00% | — | -7699.00% | -125.80% | -0.90 | 169.70% | 6.74% | -3.90% | 31.27% | -0.19 | -0.27 | — | -65.53 |
| MRKR | Marker Therapeutics, Inc. | $1.48 | 15.98M | +3,230% | -2% | — | — | -1.26 | 0.73 | 2.04 | 0.51 | — | 0.73 | -104.33% | -168.69% | -162.82% | -65.81% | 1313.50% | -54.82% | 0.00 | — | 6.36 | 6.22 | 1.73 | -3834.00% | 9906.00% | -3364.00% | -81.00% | -3.15 | 1288.92% | 0.00% | 0.00% | 30.30% | 0.51 | 0.52 | -0.87 | -26.44 |
| PHIO | Phio Pharmaceuticals Corp… | $1.14 | 12.27M | — | — | — | — | -0.14 | 0.22 | — | 0.59 | — | 0.22 | 0.00% | — | — | -114.83% | 1067.49% | -94.69% | 0.00 | — | 5.65 | 5.30 | 0.73 | -9805.00% | — | -3386.00% | -694.83% | -7.01 | 1027.89% | 0.00% | 0.00% | 0.10% | 0.59 | 0.61 | — | -38.36 |
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
- CEO
- Ryan H. Saadi
- Employees
- 18
- Beta
- -0.78
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.03) − 1 = — (DCF, example).